Skip to main content
. 2024 Oct 22;15(1):526–541. doi: 10.1016/j.apsb.2024.10.006

Figure 5.

Figure 5

In vivo targeting and anti-tumor ability of HFn@Fe/siGPX4. (A) Near-infrared fluorescence in vivo imaging images at different time points post-injection. (B) Radiation efficiency of tumor sites at different time points post-injection. Data are presented as mean ± SD (n = 3). (C) Near-infrared fluorescence images of major organs and tumors at 24 h post-injection. (D) Radiation efficiency of different tissues at 24 h post-injection. Data are presented as mean ± SD (n = 3). (E) Tumor growth curves of each MCF-7 tumor over time following different treatments. (F) Tumor growth curves of different groups of MCF-7 tumor-bearing mice after various treatments indicated. Data are presented as mean ± SD (n = 6). (G) Kaplan–Meier survival curve of MCF-7-bearing mice following different treatments. (n = 6). (H) The isolated MCF-7 tumors from the sacrificed mice following treatments. (I) Representative H&E and TUNEL stained tumor slice images after the treatment. Scale bar = 100 μm ∗∗∗∗P < 0.0001.